Jade Biosciences registers Phase 3 trial of JADE101 in IgA nephropathy
Jade Biosciences listed a new Phase 3 study, the EVERGREEN study, testing JADE101 against placebo in adults with IgA nephropathy.
Jade Biosciences had one registry update during the week, a newly listed Phase 3 trial.
- Jade Biosciences registered a Phase 3, randomized, placebo-controlled trial of JADE101, given by subcutaneous injection, in adults with immunoglobulin A nephropathy. The study is a multicenter, double-blind, placebo-controlled study evaluating the efficacy and safety of JADE101 administered subcutaneously in participants with immunoglobulin A nephropathy, known as the EVERGREEN study.1 The trial is not yet recruiting1, plans to enroll 480 participants (estimated)1, and its primary outcome is the effect of JADE101 on Urine Protein Creatinine Ratio (UPCR) in participants with IgA nephropathy, assessed at Week 521.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.